Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 4, pp 13–14 | Cite as

Schwerpunkt triple-negatives Mammakarzinom

Screening und Diagnostik

  • Sabine BucherEmail author
  • Sophie Dellas
schwerpunkt
  • 139 Downloads

Die Diagnostik des triple-negativen Mammakarzinoms kann Untersuchende vor Herausforderungen stellen, etwa wenn karzinomtypische Zeichen fehlen. Lesen Sie im Folgenden, worauf zu achten ist, damit eine adäquate Diagnosestellung gelingt.

Literatur

  1. 1.
    Obdeijn IM et al. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res Treat. 2014;144(3):577–82.CrossRefGoogle Scholar
  2. 2.
    Houssami N, Hunter K. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. NPJ Breast Cancer. 2017;13;3:12Google Scholar
  3. 3.
    Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. 2012;23(Suppl 6):vi23–9PubMedGoogle Scholar
  4. 4.
    Gao B et al. Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol 2014;87:20130496CrossRefGoogle Scholar
  5. 5.
    Dogan BE et al. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol. 2010;194(4):1160–6CrossRefGoogle Scholar
  6. 6.
    Krizmanich-Conniff KM et al. Triple receptor-negative breast cancer: imaging and clinical characteristics. AJR Am J Roentgenol. 2012;199(2):458–64CrossRefGoogle Scholar
  7. 7.
    Naehrig D et al. Das dreifach negative Mammakarzinom. Von der Diagnostik zur Therapie. Info Onkologie. 2013;16(1):26–35CrossRefGoogle Scholar
  8. 8.
    Whitman GJ et al. Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol. 2011;46(1):26–39CrossRefGoogle Scholar
  9. 9.
    Bae MS et al. Pretreatment MR imaging Features of Triple-negative Breast cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival. Radiology. 2016;281(2):392–400CrossRefGoogle Scholar
  10. 10.
    Groheux D et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breastcancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35CrossRefGoogle Scholar
  11. 11.
    Mavaddat N et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Radiologie und NuklearmedizinUniversitätsspital BaselBaselSchweiz

Personalised recommendations